Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for carotid intima-media thickness in type 2 diabetes with prior transient ischemic attack
IRCT20221101056357N3Phase 3Recruiting
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM), transient ischaemic attack (TIA) and carotid atheroma (CAS) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoint: Change in common carotid artery intima-media thickness. Started Oct 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)transient ischaemic attack (TIA)carotid atheroma (CAS)
Beyond the preview
Go deeper on IRCT20221101056357N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221101056357N3.